FDA-approved medication
Wegovy Tablets (oral semaglutide)
Key facts
Last reviewed: 2026-11-06- •FDA label says "WEGOVY (semaglutide) tablets, for oral use".
- •FDA label says "Take WEGOVY tablets orally once-daily on an empty stomach in the morning with water (up to 4 ounces). Do not take with other liquids besides water."
- •FDA label says "Swallow tablets whole. Do not split, crush, chew or dissolve."
- •FDA label says "WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition."
FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.
oral semaglutide · 1.5 mg, 4 mg, 9 mg, and 25 mg tablets · once daily (morning, empty stomach)
- Active ingredient
- oral semaglutide
- Dosage form (label)
- Oral: 1.5 mg, 4 mg, 9 mg, and 25 mg tablets
- Schedule (label)
- Once daily (morning, empty stomach)
- Strengths (label)
- Tablets: 1.5 mg, 4 mg, 9 mg, and 25 mg. Take in the morning on an empty stomach with up to 4 ounces of plain water at least 30 minutes before first food, beverage, or other oral medications of the day.DailyMed FDA Prescribing Information (NDA 218316) · Wegovy official website. Accessed November 6, 2026.
- Manufacturer
- Novo Nordisk A/S (per label)
Brand names are trademarks of their respective owners; this site is not affiliated with them.

FDA label
Wegovy Tablets dose steps (FDA label)
- 1.5 mgDays 1–30Starting dose
- 4 mgDays 31–60Dose escalation
- 9 mgDays 61–90Dose escalation
- 25 mgDay 91 & onwardMaintenance dose
FDA label answers
Common questions about Wegovy Tablets
All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, SPL version 19, revised 06/2026)).
Who are Wegovy Tablets approved for?
FDA label says "WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. ( 1 ) • to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition."
How often and when should Wegovy Tablets be taken?
FDA label says "Take WEGOVY tablets orally once-daily on an empty stomach in the morning with water (up to 4 ounces). Do not take with other liquids besides water."
What are the most common side effects listed on the label for Wegovy Tablets?
FDA label says "Most common adverse reactions (incidence ≥5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss."
Is there a boxed warning on the Wegovy Tablets label?
Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures."
What is the recommended dose escalation and maintenance for Wegovy Tablets?
FDA label says "Initiate WEGOVY tablet with a dosage of 1.5 mg once daily for 30 days. Then follow the dosage escalation schedule, titrating every 30 days to achieve the maintenance dosage. ( 2.2 ) • The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily for cardiovascular risk reduction and weight reduction in adults."
Next Steps: Evaluating Wegovy Tablets for Your Care Plan
Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.
Out-of-Pocket Expense Modeling
Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.
Consultation & Lab Checklist
Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.
BMI Qualification & Directory
Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.
Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.
Before Starting Wegovy Tablets
Gradual Dose Titration
Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.
Lifestyle & Nutrition Support
In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.
Long-Term Plan
Talk with your clinician before changing or stopping treatment.
In-Depth Clinical Guides
Explore our clinical reviews, FDA label comparisons, and insurance navigation guides for Wegovy Tablets.
Oral Wegovy Pill Overview
SNAC carrier absorption technology, morning fasting administration rules, and trial data.
Oral GLP-1 Comparison
How oral peptide semaglutide compares to non-peptide small-molecule orforglipron.
Managing GI Tolerability
Managing gastrointestinal symptoms and hydration with oral formulations.
Exploring non-injectable options?
Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.